Important class risks include gallbladder disease (cholelithiasis, cholecystitis) and, specifically for semaglutide in patients with type 2 diabetes, potential worsening of diabetic retinopathy complications in those with pre-existing retinopathy
When it comes to people with obesity and without diabetes, the 2025 AACE guidelines recommend semaglutide and tirzepatide as first line over other drug classes for a variety of conditions, including those with prediabetes, type 2 diabetes, osteoarthritis, kidney disease, heart failure, fatty liver, cardiovascular protection, and sleep apnea
Also Read: Emerging Legal Skills for Young Lawyers in India The Courts decision reflects Indias strong stance against patent evergreening, a practice where companies seek to extend monopoly rights by making minor modifications to existing drugs
What Is MDL 3094
Tricyclics (amitriptyline, nortriptyline) carried the greatest cardiometabolic burden